Intrahepatic cholestasis of pregnancy (ICP) is the commonest pregnancy-specific liver disorder in the UK. It affects around 5,500 women a year, causing premature birth and, in extreme cases, stillbirth. The most popular current drug used to treat ICP is called ursodeoxycholic acid (commonly known as 'urso'), but it hasn't been tested in any large clinical trials to show whether it prevents premature birth and stillbirth.
Our trial asked, "If a woman has ICP, what are the effects on the baby if she is treated with ursodeoxycholic acid (or placebo)?"
This week's The Lancet Child & Adolescent Health includes an article describing standardised scores for the Parent Report of Children's Abilities, Revised (PARCA-R) questionnaire. The PARCA-R is recommended for routine use in the UK to screen for developmental delay in children born preterm and can be completed by parents in 10 to 15 minutes.
A new website has also been lauched featuring an online version of the questionnaire and a pre-programmed calculator for deriving the standardised scores.
Dr Louise Linsell at NPEU collaborated with colleagues at the University of Leicester and other universities to standardise the scores.
We can now quantify a child’s developmental level relative to the UK population of two year olds, and identify advanced or delayed development. The standardised PARCA-R is freely available for parents to use and has been translated into 14 languages. It provides a reliable, cost-effective alternative to other developmental assessments that can be costly to administer.
Woman's Hour on BBC Radio 4 at 10 a.m. on Monday 15th July 2019 features a discussion on the increased maternal mortality rates among black and minority ethnic women in the UK. The discussion cites findings from MBRRACE-UK and includes the birth experiences of women who contacted the programme.
The Priority Setting Partnership in Diabetes and Pregnancy have launched their Initial Survey today. The survey is the first step in finding the unanswered questions about diabetes and pregnancy that, from the perspective of women, their support networks (families, partners, friends) and healthcare professionals, are the most important for research to address.
Women, their friends and families, and healthcare professionals with experience or interest in pregnancy with diabetes are invited to complete the survey. This can be anything about the time before, during or after pregnancy with diabetes of any type e.g. type 1, type 2, MODY, gestational diabetes and others.
By highlighting the important areas for research to funders of research and policy makers, the project will support research which will improve the healthcare and wellbeing of women and families affected by diabetes in pregnancy.
E-Freeze is a multi-centre randomised controlled trial being conducted in the UK. It compares fresh embryo transfer with frozen thawed embryo transfer for couples undergoing their first, second or third round of fertility treatment.
The main aim of E-Freeze is to understand if having a fresh or thawed embryo transfer makes any difference in the chance of having a healthy baby.
The study protocol for E-Freeze has been published in the BioMedCentral Reproductive Health journal. You can find it here.